Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.55 |
| ▸ | ITGAV | P06756 | 20/20 | 0.55 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.55 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 12/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.48 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12016720 | 0.93 | ITGB3 (0.46) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL451423 | 0.88 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL22594705 | 0.88 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL16920496 | 0.88 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL451422 | 0.87 | ITGB3 (0.52) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL19534260 | 0.84 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL34082 | 0.84 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL26970603 | 0.84 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL29403053 | 0.83 | ITGB3 (0.77) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL16923811 | 0.82 | ITGB3 (0.52) | ITGB3ITGAVITGB5ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-11-10 | — | — | US | disclosed |
| US-9051292-B2 | Sultone compound derivatives substituted by nucleophiles, in particular radionuclides, and use thereof for marking macromolecules | ADVANCED ACCELERATOR APPLICATIONS (FR) | 2015-06-09 | — | — | US | disclosed |
| WO-2011018467-A1 | SULTONE COMPOUND DERIVATIVES SUBSTITUTED BY NUCLEOPHILES, IN PARTICULAR RADIONUCLIDES, AND USE THEREOF FOR MARKING MACROMOLECULES | ADVANCED ACCELERATOR APPLICATIONS (FR) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | KIT, NISCH, FLT3 | ITGB3 3132/4885ITGAV 2306/4885ITGB5 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.